Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00669994 · ClinicalTrials.gov registry record · Phase 4

Trial to Evaluate the Efficacy and Safety of Cipro® XR in Treating Female Patients With Lower Urinary Tract Infections

A Phase 4 study of Urinary Tract Infection, sponsored by Bayer.

Completed
Registry status
Phase 4
Development phase
180
Enrollment target
20
Study locations

NCT00669994: Completed Phase 4 study of Urinary Tract Infection, sponsored by Bayer.

NCT00669994 is a Phase 4 study of Urinary Tract Infection that has completed, run by Bayer. The registered enrollment target is 180 participants, below the 657-participant average among 11 other Urinary Tract Infection trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00669994, a Phase 4 study of Urinary Tract Infection, has completed, sponsored by Bayer.

COMPLETED
Registry status
Phase 4
Development phase
180 participants
Enrollment target
20
Study locations

Study Summary

This trial evaluated how effective and safe Cipro XR was in treating female patients with signs and symptoms of a lower urinary tract infections. After 3 days of treatment, patients were evaluated to determine if signs/symptoms disappeared and the infecting bacteria was eliminated.

Conditions Studied

Urinary Tract Infection

Interventions

  • DRUG Ciprofloxacin

Study Locations (20)

California

  • - Laguna Hills
  • - Long Beach
  • - San Diego
  • - San Luis Obispo
  • - San Mateo
  • - Sylmar
  • - Yorba Linda

Alabama

  • - Birmingham
  • - Birmingham
  • - Pelham

Florida

  • - Clearwater
  • - Pembroke Pines

New Jersey

  • - Elizabeth
  • - Holmdel

Arizona

  • - Phoenix

Connecticut

  • - Avon

Indiana

  • - Evansville

Massachusetts

  • - Milford

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2003-07
Est. Completion 2003-10
Phase Phase 4
Bayer

591 total trials

What the finished NCT00669994 record still lists

NCT00669994 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 657-participant average among 11 other Urinary Tract Infection trials with a reported enrollment target (73% lower).

The record links to 1 condition, with Urinary Tract Infection appearing as the primary indexed condition, and to 1 intervention - of which Ciprofloxacin is the first listed.

NCT00669994 names 20 study sites across 10 states, led by California, Alabama, Florida.

Frequently Asked Questions

What is clinical trial NCT00669994 about?

NCT00669994 is a clinical study titled "Trial to Evaluate the Efficacy and Safety of Cipro® XR in Treating Female Patients With Lower Urinary Tract Infections". This trial evaluated how effective and safe Cipro XR was in treating female patients with signs and symptoms of a lower urinary tract infections. After 3 days of treatment, patients were evaluated to determine if signs/symptoms disappeared and the infecting bacteria was eliminated.

What is the current status of trial NCT00669994?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 180 participants. The study started on 2003-07. Estimated completion is 2003-10.

What conditions does trial NCT00669994 study?

This clinical trial studies the following conditions: Urinary Tract Infection.

What interventions are being tested in trial NCT00669994?

The interventions under investigation include: Ciprofloxacin (DRUG).

Who is sponsoring clinical trial NCT00669994?

This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00669994 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Urinary Tract Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00669994's enrollment target sits among peer trials

180 11th of 11 higher than 1 of 11 other Urinary Tract Infection trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Urinary Tract Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01558804 · 180 participants

    GRoup A StrePtococcus

  • NCT02932176 · 180 participants

    Machine Learning for Handheld Vascular Studies

  • NCT03384563 · 180 participants · Phase 4

    Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane

  • NCT03423628 · 180 participants · Phase 1

    A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00669994, the US trial registry maintained by the National Library of Medicine. NCT00669994 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.